Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect

Tirzepatide, an injectable agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, is used to treat type 2 diabetes mellitus and obesity. To our knowledge, there have been few reported cases of drug-induced liver injury (DILI) secondary to tirzepatide use. We report the experience of a 76-year-old woman who developed acute hepatitis following 8 weeks of tirzepatide use and a sixteen-pound weight loss. She was found to have elevated liver enzymes, and liver biopsy confirmed DILI. Though the mechanism underlying this DILI remains unknown, physicians should be aware of this rare side effect.